PE20081366A1 - Formulacion acuosa que comprende acido (2r)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico - Google Patents

Formulacion acuosa que comprende acido (2r)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico

Info

Publication number
PE20081366A1
PE20081366A1 PE2007001187A PE2007001187A PE20081366A1 PE 20081366 A1 PE20081366 A1 PE 20081366A1 PE 2007001187 A PE2007001187 A PE 2007001187A PE 2007001187 A PE2007001187 A PE 2007001187A PE 20081366 A1 PE20081366 A1 PE 20081366A1
Authority
PE
Peru
Prior art keywords
quinolyloxy
phenoxy
bromo
cyclodextrin
present
Prior art date
Application number
PE2007001187A
Other languages
English (en)
Inventor
Olivier Dorchies
Jiping Liu
William L Rocco
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20081366A1 publication Critical patent/PE20081366A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA FORMULACION ACUOSA QUE COMPRENDE: i) UN AGENTE ANTICANCERIGENO: ACIDO (2R)-2-[4-(7-BROMO-2-QUINOLILOXI)FENOXI]PROPANOICO PRESENTE EN UNA CANTIDAD ENTRE 0,1% A 5% (P/V); ii) UNA CICLODEXTRINA SELECCIONADA DEL GRUPO DE ALFA, BELTA, GAMMA Y DELTA-CICLODEXTRINAS, SIENDO PREFERIDAS SULFOBUTIL ETER ß-CICLODEXTRINA E HIDROXI-PROPIL ß-CICLODEXTRINA, CAPTISOL, PRESENTE EN UNA CANTIDAD ENTRE 1% A 50% (P/V); Y iii) AL MENOS UN AGENTE POTENCIADOR DE SOLUBILIDAD, TAL COMO UN AGENTE TAMPONANTE SIENDO PREFERIDO TAMPON FOSFATO DE METAL MONOALCALINO/FOSFATO DE METAL DIALCALINO EN UNA CONCENTRACION ENTRE 0,01 M A 0,25 M Y UN pH ENTRE 5 Y 8. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTA FORMULACION SE CARACTERIZA POR SER MEJORADA YA QUE REDUCE LA HEMOLISIS CAUSADA POR EL FARMACO, SIENDO DE ADMINISTRACION PARENTERAL, Y UTIL EN EL TRATAMIENTO DE UN CANCER SOLIDO TAL COMO CANCER DE COLON, MAMA, PROSTATA, OVARIO, MELANOMA Y PANCREAS
PE2007001187A 2006-09-07 2007-09-05 Formulacion acuosa que comprende acido (2r)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico PE20081366A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291410A EP1897542A1 (en) 2006-09-07 2006-09-07 Aqueous formulation comprising an antitumor agent

Publications (1)

Publication Number Publication Date
PE20081366A1 true PE20081366A1 (es) 2008-11-28

Family

ID=37728353

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001187A PE20081366A1 (es) 2006-09-07 2007-09-05 Formulacion acuosa que comprende acido (2r)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico

Country Status (16)

Country Link
EP (2) EP1897542A1 (es)
JP (1) JP2010502691A (es)
KR (1) KR20090050070A (es)
CN (1) CN101511362A (es)
AR (1) AR062674A1 (es)
AU (1) AU2007293174A1 (es)
BR (1) BRPI0717034A2 (es)
CA (1) CA2660685A1 (es)
CL (1) CL2007002598A1 (es)
IL (1) IL197072A0 (es)
MX (1) MX2009002280A (es)
PE (1) PE20081366A1 (es)
RU (1) RU2009112624A (es)
TW (1) TW200817005A (es)
UY (1) UY30579A1 (es)
WO (1) WO2008029282A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
WO2012175434A1 (en) 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE287397T1 (de) * 2001-07-31 2005-02-15 Univ Wayne State Chinoline derivate und ihre anwendung als antitumor agentien
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents

Also Published As

Publication number Publication date
IL197072A0 (en) 2009-11-18
CL2007002598A1 (es) 2008-04-18
CN101511362A (zh) 2009-08-19
BRPI0717034A2 (pt) 2014-05-20
UY30579A1 (es) 2008-03-31
JP2010502691A (ja) 2010-01-28
EP1897542A1 (en) 2008-03-12
EP2068876A2 (en) 2009-06-17
TW200817005A (en) 2008-04-16
MX2009002280A (es) 2009-03-13
CA2660685A1 (en) 2008-03-13
WO2008029282A2 (en) 2008-03-13
WO2008029282A3 (en) 2008-05-22
AU2007293174A1 (en) 2008-03-13
AR062674A1 (es) 2008-11-26
KR20090050070A (ko) 2009-05-19
RU2009112624A (ru) 2010-10-20

Similar Documents

Publication Publication Date Title
RS52913B (en) SUBcutaneous FORMULATION OF ANTI-HER2 ANTIBODIES
PE20091328A1 (es) Formulacion de anticuerpo
AR122463A2 (es) Suspensiones de nanopartículas que contienen polímero de carboxivinilo
EA201200475A1 (ru) Высококонцентрированные фармацевтические композиции, содержащие антитело к cd20
MX2010011672A (es) Conjugados del factor ix con vidas medias extendidas.
RS52633B (en) CANCER TREATMENT FORMULATION
MX2009005727A (es) Nanoparticulas de entidad anfifilica.
MY161620A (en) Oral care formulations that enhance amount of soluble zinc
SMT201300096B (it) Inibitori di prolil idrossilasi
MX352459B (es) Composiciones de eter-sulfoalquilico-ciclodextrina.
CL2008003416A1 (es) Anticuerpo monoclonal anti-anexelekto (axl); hibridoma; inhibidor de la angiogenesis, supresor del crecimiento celular, inductor de la actividad de fosforilacion de axl, agente que reduce el nivel de expresion de axl, agente anti-cancer que lo comprenden; y metodo para reducir el nivel de expresion de axl.
EP2588116A4 (en) FORMULATIONS OF AN INTRAVENOUS SOLUTION OF POSACONAZOLE STABILIZED BY SUBSTITUTED BETA CYCLODEXTRIN
EA201370175A1 (ru) Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
MY188326A (en) Agricultural chemical-spreading agent composition
AR074778A1 (es) Composicion farmaceutica, con anticuerpo monoclonal humano anti - igf-ir.
BRPI0915269A2 (pt) octonidina ou um sal farmacêutico do mesmo, kit farmacêutico, composição farmacêutica e agente farmacêutico
BR112015027607A8 (pt) métodos de tratamento de câncer de mama, de câncer da próstata, de câncer carcinoide, de câncer do ovário e de câncer do pulmão em pacientes.
CL2011000979A1 (es) Compuestos derivados ftalazina 1,4-disustituida; composicion farmaceutica; y su uso en el tratamiento del cancer.
PE20081366A1 (es) Formulacion acuosa que comprende acido (2r)-2-[4-(7-bromo-2-quinoliloxi)fenoxi]propanoico
BR112021013362A2 (pt) Agentes rnai para inibição da expressão de hif-2 alfa (epas1), suas composições e métodos de uso
NZ598518A (en) Concentrated polypeptide formulations with reduced viscosity
GB2462761A (en) Protein formulation
MY150054A (en) Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
TN2012000516A1 (en) Stable ready to use injectable paracetamol formulation
AR114134A2 (es) Sal de maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaeno

Legal Events

Date Code Title Description
FA Abandonment or withdrawal